PF-06651600

PF-06651600

Biochem/physiol Actions

PF-06651600 specifically targets the ATP (adenosine triphosphate)-binding domain of JAK3 (Janus kinase 3). Loss of function of JAK3 is associated with severe combined immunodeficiency syndrome.

PF-06651600 is a potent and selective JAK3 inhibitor.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573735 PF-06651600 white to beige 100 QMPMPSGDPRHZCG-VZXYPILPSA-N 1S/C15H19N5O.C3H4O4/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;4-2(5)1-3(6)7/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);1H2,(H,4,5)(H,6,7 SIGMA-ALDRICH powder ≥98% (HPLC)
£402.54 (exc VAT) per 25MG
-
+
3573736 PF-06651600 white to beige 100 QMPMPSGDPRHZCG-VZXYPILPSA-N 1S/C15H19N5O.C3H4O4/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15;4-2(5)1-3(6)7/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19);1H2,(H,4,5)(H,6,7 SIGMA-ALDRICH powder ≥98% (HPLC)
£140.68 (exc VAT) per 5MG
-
+